Altria FDA statements investigation

Levi & Korsinsky, a shareholder rights litigation firm, has commenced an investigation into Altria Group, Inc. (NYSE: MO) concerning potential violations of federal securities laws. The investigation focuses on statements made by Altria executives on the April 30, 2026 earnings call regarding the FDA regulatory status of its on! PLUS nicotine pouch product and the expected timing of FDA authorizations for additional pending applications. CEO Billy Gifford described on! PLUS as 'the first and only product authorized under the FDA's pilot program' and stated that the science behind pending applications 'provides a basis for FDA authorization within the 180-day statutory time line.' The investigation questions whether these characterizations accurately reflected the FDA's review status at the time. On July 30, 2026, Altria's stock fell sharply after the company reported second-quarter results below consensus on earnings and revenue and lowered its full-year outlook. CFO Salvatore Mancuso had previously reaffirmed 2026 adjusted diluted EPS guidance of $5.56 to $5.72, which was subsequently revised downward. Levi & Korsinsky is investigating whether Altria adequately disclosed the regulatory and financial risks tied to these statements.